Full Press Release Details
Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
Raanana, Israel, March 25, 2025 (GLOBE
NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech
company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies
for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its
proprietary drug delivery platform.
According to the World Health Organization (WHO), epilepsy is a neurological
condition affecting about 50 million people worldwide. Many existing therapies fail to provide adequate control of acute repetitive seizures
and may come with undesirable adverse effects. The global acute repetitive seizures market size was estimated at USD 3.15
billion in 2024 and is projected to grow at a CAGR of 12.7% from 2025 to 2030.
According to the latest research study, the global epilepsy treatment
devices market was valued at approximately USD 526.8 Million in 2023 and is expected to reach a value of around USD 787.3 Million by 2033,
growing at a compound annual growth rate (CAGR) of about 4.1% during the forecast period 2024 to 2033.
The study will be conducted in collaboration with Professor Fabio Sonvico,
Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal
and pulmonary drug delivery solutions and a member of the Company's Scientific Advisory Board.
These preclinical studies mark a step
forward in evaluating Polyrizon's Trap and Target (T&T) platform for the intranasal administration of
Benzodiazepine, designed to enable rapid, targeted, and patient-friendly seizure rescue therapy. The studies will assess key
parameters, such as drug loading capacity, release kinetics, nasal deposition and stability using a model molecule, that simulates
the behavior of intranasal benzodiazepines at this early stage, laying the groundwork for further safety and efficacy testing in
preclinical and clinical studies.
BZDs are well-established, first-line drugs for the acute treatment
of seizures. They act by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at the GABA-A receptor in the central nervous
system, helping to quickly suppress seizure activity.
Intranasal delivery of BZDs offers multiple advantages over traditional
routes of administration, including ease of use and increased accessibility. This approach allows emergency responders, caregivers and
at-risk individuals to administer life-saving medication rapidly and independently in out-of-hospital settings.
"Launching this preclinical program marks an important milestone
in our initiative to improve emergency treatment options for epilepsy patients," said Tomer Izraeli, CEO of Polyrizon. "We
believe our intranasal delivery platform has the potential to offer a faster, safer and more accessible solution for managing acute seizures
outside of clinical settings."
Polyrizon is a development stage biotech company
specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based
shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial
tissue. Polyrizon's proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture
of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a "biological mask"
with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel
technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers
to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical
ingredients, or APIs, as Trap and Target , or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as
"expects," "anticipates," "intends," "plans," "believes," "seeks,"
"estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example,
the Company is using forward-looking statements when it discusses its initiative to improve emergency treatment options for epilepsy patients,
its belief that its intranasal delivery platform has the potential to offer a faster, safer and more accessible solution for managing
acute seizures outside of clinical settings and the expected growth of the global acute repetitive seizures and epilepsy treatment devices
markets. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and
projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good
faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results
may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject
to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking
statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's
reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks
detailed in the Company's annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking
statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to
reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking
information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements,
no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking
statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not
incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.